NEW YORK (GenomeWeb News) – German firm Evotec said today that it will buy the zebrafish screening operations of UK company Summit for around £500,000 ($754,000).

The small molecule drug developer plans to use the new Summit operations in Abingdon, UK, and in Singapore, to prioritize promising compounds early in the drug discovery process.

Summit had agreements with a number of drug makers, including a three-year alliance with Johnson & Johnson, and collaborations with Bayer-Schering, Merck KGaA, Roche, and others.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.